We are the only licensed contract and development manufacturer of CAR T-cell therapeutics in New Zealand, with a world-class team of scientists and consultants who are dedicated to helping you bring your cell therapy to patients from around the globe. We’ll keep your manufacturing costs under control, we’ll reduce the time from patient blood isolation to CAR T-cell infusion and we’ll follow a continuous improvement approach as your therapy progresses through the journey to commercialisation.

BioOra

CONGRATULATIONS to our sibling company on their lab opening.

 This is a great video with presentations by Callaghan Innovation on their strategy to enable great biotechs to build out from the great research is being done all over NZ.  Also, a really inspiring presentation from the Bridgewest Ventures NZ Ventures Managing Partner, Saum Vahdat on the vision Bridgewest Group have for biotech in NZ and how it will benefit New Zealanders.  Great to hear also the nod to the pioneering work that is happening every day at the Malaghan Institute of Medical Research which has given birth to NZ's growing cell, viral and mRNA therapy capability.

Tu meke!

Great piece on the clinical trials progress with our partners Malaghan Institute of Medical Research.  BioOra is excited to be the commercial partner in the automated manufacturing to ensure the manufacturing capability in NZ and beyond keeps up with the clinical progress.

The BioOra team and its partners are excited to welcome Dr Andi Grant as CEO.  Andi will lead us on our journey towards becoming a global leader in the automated manufacture and end to end delivery of personalised cell therapies.  

Andi is a dynamic leader and value creator, with global experience in development and patient access to medical innovations through roles in the pharmaceutical and biotech sector. 

Read more in the press release:  https://lnkd.in/gBWk4DKP 

Malaghan Institute of Medical Research 
Bridgewest Ventures NZ 
Bridgewest Group

Congratulations to Dr Tol Trimborn and the rest of the CellPoint team on their recent $131M+ sale to Galapagos! 

CAR T-cell therapy has revolutionized the treatment of blood cancers and has saved countless lives while also lowering treatment times and reducing the harmful side effects associated with traditional therapies. Under existing approved indications alone, CAR T-cell therapy has the potential to be the new standard of care and deliver hope to over one million patients around the world per year.
 
As promising as CAR T-cell therapy is, there are significant bottlenecks in the production process of CAR T-cells that significantly lowers the availability of treatment, lengthens patients’ treatment time, and increases costs associated with the actual therapy. A patient’s blood sample may be shipped from one country to another for CAR T-cell manufacture and then shipped back to the patient for infusion. Existing manual manufacture of CAR T-cells requires upwards 50 hours of operator time. To reduce operator time, production cost and timelines, BioOra and CellPoint are hard at work developing automated means of production for CAR T-cell therapy. Utilizing closed system cocoons, manufactured by the Swiss pharmaceutical company Lonza, processes being developed by BioOra and CellPoint will be able reduce the time of production and treatment to twelve days versus several weeks using conventional methods. BioOra and CellPoint will also increase the global reach of CAR T-cell treatment for cancer patients enabling future access and more effective point of treatment care for hundreds of thousands of cancer patients to this life-saving treatment.
 
We at BioOra are confident that the continued leadership of Dr Tolleiv Trimborn combined with the significant capital and expertise brought to the table by Galapagos NV will enable CellPoint to continue developing this revolutionary production process and eventually enable them to scale their business and treat tens of thousands of patients. We could not be prouder of the team at CellPoint and we are thrilled to see the revolutionary production process that both of our companies are progressing being validated by a major player in the market.

#cartcelltherapy #innovation #acquisition #celltherapy #business

BeiGene is a biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer.

BeiGene

Regeneron Pharmaceuticals is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Regeneron Pharmaceuticals

Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer.

Allogene Therapeutics

Anixa Biosciences is a biotechnology company focused on harnessing the body's immune system to fight cancer.

Anixa Biosciences

Autolus Therapeutics is a biopharmaceutical company focused on the development and commercialization of next-generation engineered T-cell therapies for cancer.

Autolus Therapeutics

BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other serious diseases.

BioNTech

BioOra is a company that aims to make CAR T-cell therapy accessible to everyone, regardless of location, income, or background, by developing advanced manufacturing technologies and clinical models of care.

news impact assignment basic	general	May 3, 2024 5:46 AM	40cbb1d2
public peers	general	May 3, 2024 5:46 AM	3750dc54
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 3, 2024 5:46 AM	e8d0c019
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	May 3, 2024 5:46 AM	2eb7177d
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 3, 2024 5:46 AM	44aa2492
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:BIOORA

BioOra